Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717089 | 1.00 | DRD2 (0.53) | DRD2ABCG2KDM4ECYP1A2MCHR2 | |
| SCHEMBL1717318 | 1.00 | DRD2 (0.53) | DRD2ABCG2KDM4ECYP1A2MCHR2 | |
| SCHEMBL1717261 | 0.89 | DRD2 (0.44) | DRD2ABCG2KDM4ECYP1A2MCHR2 | |
| SCHEMBL2982123 | 0.89 | DRD2 (0.44) | DRD2ABCG2KDM4ECYP1A2MCHR2 | |
| SCHEMBL2984590 | 0.86 | DRD2 (0.56) | DRD2ABCG2KDM4EALDH1A1LMNA | |
| SCHEMBL1717072 | 0.86 | DRD2 (0.56) | DRD2ABCG2KDM4EALDH1A1LMNA | |
| SCHEMBL5785661 | 0.84 | DRD2 (0.51) | DRD2ABCG2KDM4EALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL2977334 | 0.84 | DRD2 (0.51) | DRD2ABCG2KDM4EALDH1A1LMNA | |
| SCHEMBL1717406 | 0.82 | DRD2 (0.50) | DRD2ABCG2KDM4EALDH1A1LMNA | |
| SCHEMBL1718814 | 0.82 | DRD2 (0.50) | DRD2ABCG2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656373-B1 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINEANTAGONISTS | SANOFI SA (FR) | 2012-01-18 | — | — | EP | claimed |
| EP-1656373-B1 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINEANTAGONISTS | SANOFI SA (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-7777041-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
| US-7504511-B2 | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-20060135575-A1 | 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-06-22 | — | — | US | disclosed |
| EP-1656373-A2 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINEANTAGONISTS | Sanofi-Aventis (FR) | 2006-05-17 | — | — | EP | disclosed |
| WO-2004096798-A2 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINE ANTAGONISTS | SANOFI-AVENTIS (FR) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135575-A1 | 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | PAH, ABAT, AADAT | DRD2 4471/4885ABCG2 60/4885KDM4E 1082/4885 |
| US-20090156574-A1 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | PAH, ABAT, AADAT | DRD2 4471/4885ABCG2 60/4885KDM4E 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.